Price
No data yet.
Social Signal Score
Analyst Ratings
9 analystsRevenue
$755.0KAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- George Magrath
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 28
- Beta
- 0.62
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -4.84
Financials
Revenue
$755.0K+655.0%Net Income
$-8.10MEBITDA
$-7.55MFree Cash Flow
$-11.95MEPS (diluted)
$-0.08Shares Outstanding (diluted)
111.38M+1470.6%Operating Expenses
$17.23MCash & Debt
$88.81MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $14.20M | $-49.59M | $-0.80 |
| 2024 | $10.99M | $-57.53M | $-2.15 |
| 2023 | $19.05M | $-9.99M | $-0.46 |
| 2022 | $39.85M | $17.89M | $0.90 |
| 2021 | $589.0K | $-56.69M | $-3.82 |
| 2020 | $0.00 | $-24.62M | $-5.28 |
| 2019 | $0.00 | $-6.17M | $-0.87 |
Valuation
IRDhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+20.00%Social Signal Score
Mentions (4)
- Newsmarketbeat.com·6h ago·Positive
Opus Genetics Eyes 2029 Runway as Presbyopia Drop Wins FDA Approval Opus Genetics NASDAQ: IRD outlined commercialization expectations for its newly approved presbyopia eye drop, progress across its inherited retinal disease gene therapy pipeline and its funding strategy during an investor panel featuring Chief Executive Officer Dr. George Magrath and Chief Financial Officer Rob Gagnon.
View source ↗ - Newsglobenewswire.com·4d ago·Negative
…velopment of a potential treatment for this disease with high unmet need RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for OPGx…
View source ↗ - Newsglobenewswire.com·9d ago·Negative
…EGA-3 trials, which met primary and all key secondary efficacy endpoints RESEARCH TRIANGLE PARK, N.C., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental New Drug Application (sNDA)…
View source ↗ - Newsglobenewswire.com·12d ago·Neutral
Opus Genetics to Present at the Chardan Annual Healthcare Conference RESEARCH TRIANGLE PARK, N.C., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), announced today that management will present at the Chardan Annual Healthcare Conference on Tuesday, October 20, 2026 at 10:00 a.m.
View source ↗
Earnings
Wed, Nov 11(in 2 weeks)
Consensus estimate $-0.14 per share
Typical surprise -27.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.14 vs $-0.16beat
- Tue, May 12$-0.75 vs $-0.16miss
- Tue, Mar 10$-0.14 vs $-0.11miss
- Wed, Nov 12$-0.25 vs $-0.14miss
- Wed, Aug 13$-0.12 vs $-0.25beat
- Thu, May 15$-0.24 vs $-0.34beat
Estimates and results for IRD via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by IRD officers and directors.
- Bought
- $532k
- Sold
- $19.3m
6 trades
18 trades
- Foundation Fighting Blindness Retinal Degeneration Fundsold
- Gagnon Robert E.sold
- Yerxa Benjamin Rsold
- Schachle Joseph Ksold
- Magrath Georgesold
- Gagnon Robert E.sold
- Foundation Fighting Blindness Retinal Degeneration Fundsold
- Yerxa Benjamin Rsold
76 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in IRD.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.